Twist Bioscience Q3 Revenue Jumps 23% to $118M, But Losses Widen; CEO Adopts 10b5-1 Plan
TWST has more than doubled off its 52-week low of $23.3.
Summary
Twist Bioscience reported Q3 FY2026 revenue of $118.4M (+23% YoY) but swung to a net loss of $35.1M. The CEO, President, and a director adopted 10b5-1 plans for potential sales of up to 720,906 shares, adding to recent insider selling.
Key Events · Earnings and Guidance · TWST
-
Revenue Growth, But Losses Widen
Q3 revenue rose 23% to $118.4M, but the company posted a net loss of $35.1M vs. a $20.4M profit a year ago. Nine-month net loss widened to $109.6M from $50.5M.
-
Gross Margin Pressure
Gross margin declined to 52.8% from 53.4% in Q3 FY2025, primarily due to customer mix, despite higher revenues.
-
Cash Burn Accelerates
Cash, equivalents, and short-term investments fell to $166.8M from $232.4M at fiscal year-end. Operating cash burn was $41.3M for nine months, up from $35.8M.
-
CEO and Insiders Adopt 10b5-1 Plans
CEO Emily Leproust adopted a plan to sell up to 624,134 shares; President Patrick Finn up to 78,355 shares; Director Robert Chess up to 18,417 shares. This follows $12.6M in insider sales over the past 90 days.
Analysis · TWST · Life Sciences
Record quarterly revenue of $118.4 million—a 23% year-over-year surge—underscores robust demand in DNA synthesis and NGS applications. Yet the top-line strength was overshadowed by a swing to a net loss of $35.1 million, compared with a profit a year ago, pushing the nine-month loss to $109.6 million. Gross margin slipped to 52.8% from 53.4%, pressured by customer mix. Cash reserves contracted to $166.8 million from $232.4 million at fiscal year-end, though management asserts sufficient liquidity for at least 12 months. In a separate development, the CEO, President, and a director adopted 10b5-1 trading plans covering up to 720,906 shares combined, extending a pattern of insider selling that has exceeded $12.6 million in the past 90 days. While the $200 million ATM program remains untapped, the shelf registration and insider selling plans create an overhang.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TWST was trading at $101.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $23.30 to $105.47. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.